ASH: Triplet combination regimens demonstrate high response rates in multiple leukemias
ABSTRACTS: 216, 219, 1011
SAN DIEGO ― Three clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated significant positive results from novel triplet therapies in the treatment of relapsed or refractory and newly diagnosed leukemias. The results were presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition. More information on all ASH Annual...
ASH: Monoclonal antibody therapy improves survival in cancer-associated hyper-inflammatory disorder
ABSTRACT: 805
SAN DIEGO – Adult patients with newly diagnosed malignancy-associated hemophagocytic lymphohistiocytosis (mHLH) – a rare...
Novel CAR T cell therapy obe-cel demonstrates high response rates in adult patients with advanced B-cell ALL
Patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (ALL) who were treated with the novel anti-CD19 chimeric...
MD Anderson launches Institute for Cell Therapy Discovery & Innovation to deliver transformational new therapies
The University of Texas MD Anderson Cancer Center today announced the launch of its Institute for Cell Therapy Discovery & Innovation, which will build upon longstanding MD Anderson clinical and research expertise to lead the world in developing and advancing impactful cell therapies for patients in need.
The institute will bring together top scientists and clinicians to lead exceptional discovery, translational and clinical...
Novel triplet regimen yields promising response in advanced-phase chronic myeloid leukemia
According to researchers at The University of Texas MD Anderson Cancer Center, 80% of patients with previously untreated or relapsed/refractory...
ESMO: Combination therapy reduced agitated delirium in patients with advanced cancers
ABSTRACT: 1476O
BARCELONA, Spain ― Treatment with a combination of haloperidol and lorazepam reduced symptoms of agitated delirium,...
NK cells expressing interleukin-21 show promising antitumor activity in glioblastoma cells
Natural killer (NK) cells engineered to express interleukin-21 (IL-21) demonstrated sustained antitumor activity against glioblastoma stem...
CAR NK cells with CD28 costimulation improved cell persistence and antitumor activity
Adding CD28 costimulation to cord blood-derived chimeric antigen receptor (CAR) natural killer (NK) cells targeting CD70+ cancers significantly...
ASCO: Novel CAR T therapy and shorter targeted therapy durations show promise for patients with leukemia
ABSTRACTS: 6504, 6507
Researchers from The University of Texas MD Anderson Cancer Center presented positive clinical results from two...
End-of-life systemic treatment for patients with advanced cancers does not improve survival
Patients with very advanced solid tumors saw no significant improvement in overall survival after receiving systemic therapy, according to...
Immunotherapy before surgery leads to promising long-term survival in sarcoma patients
Patients with soft-tissue sarcoma treated with neoadjuvant, or pre-surgical, immunotherapy had very little residual tumor at the time of surgery...
CD19-targeted CAR NK cell therapy achieves promising one-year results in patients with B-cell malignancies
Researchers from The University of Texas MD Anderson Cancer Center reported promising results in a Phase I/II trial of 37 patients with...